A new UCLA AIDS Institute study has found that gene therapy can be developed as a safe and active technique to combat HIV.
Researchers involved in this first-of-its-kind study found that cell-delivered gene transfer has the potential to be a once-only treatment that reduces viral load, preserves the immune system and avoids lifelong antiretroviral therapy. The study appears in the current online edition of the journal Nature Medicine.
Though modest, the results do show some promise that gene therapy can be developed as a potentially effective treatment for HIV, said lead investigator Dr. Ronald Mitsuyasu, professor of medicine and director of the Center for Clinical AIDS Research and Education (CARE) at the David Geffen School of Medicine at UCLA.
"It is the first randomized controlled study done with gene therapy in HIV," said Mitsuyasu, who is also an associate director of the UCLA AIDS Institute. "What we were able to demonstrate was that the patients who received the gene-modified cells had a somewhat better suppression of their HIV viral replication after discontinuing their highly active antiretroviral therapy (HAART) treatment, compared with the controls."
This was the first randomized, double-blind, placebo-controlled gene-transfer clinical trial and involved 74 HIV-positive adults.
The patients received their own blood stem cells, either untreated or modified to carry a molecule called OZ1, which prevents viral replication by targeting a key HIV gene. OZ1 was safe, causing no adverse effects over the course of the 100-week trial.
At the primary end-point, the difference in viral load between the OZ1 and placebo group at weeks seven and eight, after they had stopped HAART treatment, was not statistically significant. But other viral parameters did demonstrate better HIV suppression and improvement in the counts of CD4+ lymphocytes — the cell population that is depleted by HIV.
The technique still needs to be developed further and perfected, Mitsuyasu said.
"Part of the reason that we didn't see a larger effect is that the persistence of the anti-HIV gene in the patient's blood was not as long as we would have liked," he said. "We need to find better ways to get the genes into the patients and maintain them, which could include using different vectors to get the gene into the cells or conditioning the patients prior to gene transfer."
Still, the results indicate that gene therapy could eventually be a useful tool in the fight against AIDS, said study co-author Dr. Thomas C. Merigan, the George and Lucy Becker Professor of Medicine emeritus at the Stanford University School of Medicine. He agrees that more needs to be done to perfect it.
"But in the way we set up the trial with randomized placebo controls, we could dissect out that there was a positive effect in patients who had the gene successfully installed," Merigan said. "This could be a first step in developing a new method of controlling a chronic infectious disease."
This study was funded by Johnson and Johnson Research Pty Limited. Grants from the National Institutes of Health also helped support part of the research.
In addition to Mitsuyasu and Merigan, authors are Andrew Carr, Jerome A Zack, Mark A. Winters, Cassy Workman, Mark Bloch, Jacob Lalezari, Stephen Becker, Lorna Thornton, Bisher Akil, Homayoon Khanlou, Robert Finlayson, Robert McFarlane, Don E. Smith, Roger Garsia, David Ma, Matthew Law, John M. Murray, Christof von Kalle, Julie A. Ely, Sharon M. Patino, Alison E. Knop, Philip Wong, Alison V. Todd, Margaret Haughton, Caroline Fuery, Janet L. Macpherson, Geoff P. Symonds, Louise A. Evans, Susan M. Pond and David A. Cooper.
Cite This Page: